2010-2022

• Organ specificity of immune cells
• New mechanism of Daclizumab-therapeutic effect on MS

1. JEM 2010
2. Ann Neurol 2011
3. Nat Rev Immunol 2011

• Current situation and development trend of neurology in China

1. Neurology 2011

• NMOSD treated with modified dose rituximab

1. Neurology 2013

• Understanding of MOG-Ab related diseases
• New understanding of clinical imaging in NMOSD

1. Neurology 2015a, b
2. Neurology N2 2015
3. Sci China Life Sci 2016

• MS repair mechanism
• NMOSD-selective CNS damage mechanism

1. Nat Neurosci 2016
2. JImmunol 2016
3. Brain Behav Immun 2017

• NMOSD treated with MSC, BTZ

1. CNS Neurosci Ther 2016
2. JAMA Neurol 2017

• TANGO experiment
• Incidence of neuroimmunological diseases in China
• MS and NMOSD patients management during Corona Virus Disease:Chinese experience
• Normal aging and immunity

1. Lancet Neurol 2020
2. Lancet RH 2020
3. Neurology N2 2020
4. Nat Neurosci 2021

2010-2022

• 脑缺血后免疫细胞脑迁移的机制和作用

1. PNAS 2014a

• 完成脑出血、脑缺血免疫干预的临床概念性研究

1. JAMA Neurol 2014
2. PNAS 2014b

• 芬戈莫德减轻tPA相关出血转化
• 系统总结脑卒中的免疫干预策略

1. Circulation 2015
2. Nat Rev Neurol 2015

• 卒中后免疫抑制的机制和临床意义
• 免疫干预延长tPA时间窗
• 明确卒中后小胶质细胞作用
• 卒中后自身免疫

1. Stroke 2016
2. JCBFM 2016, 2017
3. Immunity 2017
4. PNAS 2017
5. Ann Neurol 2018
6. Stroke 2018

• 提出脑卒中后神经炎症扩散假说
• 研发脑卒中的体液标记物

1. Lancet Neurol 2019

• 脑卒中后启动炎症的总开关
• 骨髓造血系统保护作用的神经信号通路
• 免疫干预减少tPA出血转化

1. J Exp Med 2020
2. Sci Transl Med 2021a
3. Sci Transl Med 2021b
4. Circ Res 2021

The 10-year journey of the NT team in the research and translation of stroke immunology: From 2010 to 2021, NT has completed a series of explorations in the organic integration of clinical and basic science research in stroke immune mechanism and immune intervention. We won the first prize of Tianjin Natural Science Award and China Stroke Awards two times. We possess solid foundation for market transformation.